EyeGene Inc
EyeGene Inc. engages in the research and development of biopharmaceutical drugs for the treatment and prevention of age-related diseases in South Korea. Its product pipeline comprises EG-Mirotin, which has completed Phase 2a clinical trial to treat diabetic retinopathy; EG-Decorin which completed Phase 2 clinical trial for the treatment of pressure ulcers and wound healing; and EG-Myocin, which h… Read more
EyeGene Inc (185490) - Total Liabilities
Latest total liabilities as of September 2025: ₩12.55 Billion KRW
Based on the latest financial reports, EyeGene Inc (185490) has total liabilities worth ₩12.55 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
EyeGene Inc - Total Liabilities Trend (2014–2024)
This chart illustrates how EyeGene Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
EyeGene Inc Competitors by Total Liabilities
The table below lists competitors of EyeGene Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Borlease Otomotiv A.S.
IS:BORLS
|
Turkey | TL6.08 Billion |
|
Hun Yenilenebilir Enerji Uretim AS
IS:HUNER
|
Turkey | TL3.96 Billion |
|
Latvian Forest Company AB (publ)
F:2FD
|
Germany | €7.90 Million |
|
Garden Stage Limited Ordinary Shares
NASDAQ:GSIW
|
USA | $12.56 Million |
|
Pusan Cast Iron Co., Ltd.
KO:005030
|
Korea | ₩212.67 Billion |
|
WIN HANVERKY
MU:N2R
|
Germany | €1.39 Billion |
|
CyberCatch Holdings Inc.
V:CYBE
|
Canada | CA$1.51 Million |
Liability Composition Analysis (2014–2024)
This chart breaks down EyeGene Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.19 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.29 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how EyeGene Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for EyeGene Inc (2014–2024)
The table below shows the annual total liabilities of EyeGene Inc from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩14.98 Billion | +8.83% |
| 2023-12-31 | ₩13.77 Billion | +0.85% |
| 2022-12-31 | ₩13.65 Billion | -14.79% |
| 2021-12-31 | ₩16.02 Billion | -49.18% |
| 2020-12-31 | ₩31.53 Billion | +11.49% |
| 2019-12-31 | ₩28.28 Billion | -7.88% |
| 2018-12-31 | ₩30.70 Billion | +370.07% |
| 2017-12-31 | ₩6.53 Billion | +175.39% |
| 2016-12-31 | ₩2.37 Billion | +51.49% |
| 2015-12-31 | ₩1.57 Billion | -7.33% |
| 2014-12-31 | ₩1.69 Billion | -- |